| Dr Sedrick A Salisbury, MD | |
|
325 Park St, Lebanon, OR 97355-4229 | |
| (541) 451-7200 | |
| Not Available |
| Full Name | Dr Sedrick A Salisbury |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 39 Years |
| Location | 325 Park St, Lebanon, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174568638 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | MD15516 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Samaritan Lebanon Community Hospital | Lebanon, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mid-valley Healthcare Inc | 2769391523 | 134 |
News Archive
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of PRM-151 will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology, being held May 1-5, 2011 in Ft. Lauderdale, FL.
Silence Therapeutics plc announces the issuance of two new patents by the United States Patent and Trademark Office (USPTO) which are broadly directed to double-stranded short interfering RNA (siRNA) sequences against the validated cancer targets epidermal growth factor receptor related protein (EGFR-RP) and vascular endothelial growth factor receptor 1 (VEGFR1).
Using a robot to treat brain aneurysms is feasible and could allow for improved precision when placing stents, coils and other devices, according to late breaking science presented today at the American Stroke Association's International Stroke Conference 2020.
Researchers for the first time have developed a method to track through the human body the movement of polycyclic aromatic hydrocarbons, or PAHs, as extraordinarily tiny amounts of these potential carcinogens are biologically processed and eliminated.
› Verified 4 days ago
| Entity Name | Mid-valley Healthcare Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689625980 PECOS PAC ID: 2769391523 Enrollment ID: O20031111000297 |
News Archive
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of PRM-151 will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology, being held May 1-5, 2011 in Ft. Lauderdale, FL.
Silence Therapeutics plc announces the issuance of two new patents by the United States Patent and Trademark Office (USPTO) which are broadly directed to double-stranded short interfering RNA (siRNA) sequences against the validated cancer targets epidermal growth factor receptor related protein (EGFR-RP) and vascular endothelial growth factor receptor 1 (VEGFR1).
Using a robot to treat brain aneurysms is feasible and could allow for improved precision when placing stents, coils and other devices, according to late breaking science presented today at the American Stroke Association's International Stroke Conference 2020.
Researchers for the first time have developed a method to track through the human body the movement of polycyclic aromatic hydrocarbons, or PAHs, as extraordinarily tiny amounts of these potential carcinogens are biologically processed and eliminated.
› Verified 4 days ago
| Entity Name | Good Samaritan Hospital Corvallis |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962453134 PECOS PAC ID: 1557270725 Enrollment ID: O20031125000163 |
News Archive
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of PRM-151 will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology, being held May 1-5, 2011 in Ft. Lauderdale, FL.
Silence Therapeutics plc announces the issuance of two new patents by the United States Patent and Trademark Office (USPTO) which are broadly directed to double-stranded short interfering RNA (siRNA) sequences against the validated cancer targets epidermal growth factor receptor related protein (EGFR-RP) and vascular endothelial growth factor receptor 1 (VEGFR1).
Using a robot to treat brain aneurysms is feasible and could allow for improved precision when placing stents, coils and other devices, according to late breaking science presented today at the American Stroke Association's International Stroke Conference 2020.
Researchers for the first time have developed a method to track through the human body the movement of polycyclic aromatic hydrocarbons, or PAHs, as extraordinarily tiny amounts of these potential carcinogens are biologically processed and eliminated.
› Verified 4 days ago
| Entity Name | Samaritan North Lincoln Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306897491 PECOS PAC ID: 7911816301 Enrollment ID: O20040120000329 |
News Archive
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of PRM-151 will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology, being held May 1-5, 2011 in Ft. Lauderdale, FL.
Silence Therapeutics plc announces the issuance of two new patents by the United States Patent and Trademark Office (USPTO) which are broadly directed to double-stranded short interfering RNA (siRNA) sequences against the validated cancer targets epidermal growth factor receptor related protein (EGFR-RP) and vascular endothelial growth factor receptor 1 (VEGFR1).
Using a robot to treat brain aneurysms is feasible and could allow for improved precision when placing stents, coils and other devices, according to late breaking science presented today at the American Stroke Association's International Stroke Conference 2020.
Researchers for the first time have developed a method to track through the human body the movement of polycyclic aromatic hydrocarbons, or PAHs, as extraordinarily tiny amounts of these potential carcinogens are biologically processed and eliminated.
› Verified 4 days ago
| Entity Name | Samaritan Pacific Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174888010 PECOS PAC ID: 2466353529 Enrollment ID: O20040204000304 |
News Archive
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of PRM-151 will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology, being held May 1-5, 2011 in Ft. Lauderdale, FL.
Silence Therapeutics plc announces the issuance of two new patents by the United States Patent and Trademark Office (USPTO) which are broadly directed to double-stranded short interfering RNA (siRNA) sequences against the validated cancer targets epidermal growth factor receptor related protein (EGFR-RP) and vascular endothelial growth factor receptor 1 (VEGFR1).
Using a robot to treat brain aneurysms is feasible and could allow for improved precision when placing stents, coils and other devices, according to late breaking science presented today at the American Stroke Association's International Stroke Conference 2020.
Researchers for the first time have developed a method to track through the human body the movement of polycyclic aromatic hydrocarbons, or PAHs, as extraordinarily tiny amounts of these potential carcinogens are biologically processed and eliminated.
› Verified 4 days ago
| Entity Name | Albany General Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154372340 PECOS PAC ID: 9931097987 Enrollment ID: O20040310000310 |
News Archive
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of PRM-151 will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology, being held May 1-5, 2011 in Ft. Lauderdale, FL.
Silence Therapeutics plc announces the issuance of two new patents by the United States Patent and Trademark Office (USPTO) which are broadly directed to double-stranded short interfering RNA (siRNA) sequences against the validated cancer targets epidermal growth factor receptor related protein (EGFR-RP) and vascular endothelial growth factor receptor 1 (VEGFR1).
Using a robot to treat brain aneurysms is feasible and could allow for improved precision when placing stents, coils and other devices, according to late breaking science presented today at the American Stroke Association's International Stroke Conference 2020.
Researchers for the first time have developed a method to track through the human body the movement of polycyclic aromatic hydrocarbons, or PAHs, as extraordinarily tiny amounts of these potential carcinogens are biologically processed and eliminated.
› Verified 4 days ago
| Entity Name | Samaritan North Lincoln Hospital |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1306897491 PECOS PAC ID: 7911816301 Enrollment ID: O20061104000117 |
News Archive
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of PRM-151 will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology, being held May 1-5, 2011 in Ft. Lauderdale, FL.
Silence Therapeutics plc announces the issuance of two new patents by the United States Patent and Trademark Office (USPTO) which are broadly directed to double-stranded short interfering RNA (siRNA) sequences against the validated cancer targets epidermal growth factor receptor related protein (EGFR-RP) and vascular endothelial growth factor receptor 1 (VEGFR1).
Using a robot to treat brain aneurysms is feasible and could allow for improved precision when placing stents, coils and other devices, according to late breaking science presented today at the American Stroke Association's International Stroke Conference 2020.
Researchers for the first time have developed a method to track through the human body the movement of polycyclic aromatic hydrocarbons, or PAHs, as extraordinarily tiny amounts of these potential carcinogens are biologically processed and eliminated.
› Verified 4 days ago
| Entity Name | Mid-valley Healthcare Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1689625980 PECOS PAC ID: 2769391523 Enrollment ID: O20061104000140 |
News Archive
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of PRM-151 will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology, being held May 1-5, 2011 in Ft. Lauderdale, FL.
Silence Therapeutics plc announces the issuance of two new patents by the United States Patent and Trademark Office (USPTO) which are broadly directed to double-stranded short interfering RNA (siRNA) sequences against the validated cancer targets epidermal growth factor receptor related protein (EGFR-RP) and vascular endothelial growth factor receptor 1 (VEGFR1).
Using a robot to treat brain aneurysms is feasible and could allow for improved precision when placing stents, coils and other devices, according to late breaking science presented today at the American Stroke Association's International Stroke Conference 2020.
Researchers for the first time have developed a method to track through the human body the movement of polycyclic aromatic hydrocarbons, or PAHs, as extraordinarily tiny amounts of these potential carcinogens are biologically processed and eliminated.
› Verified 4 days ago
| Entity Name | Samaritan Pacific Health Services Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1801847066 PECOS PAC ID: 2466353529 Enrollment ID: O20061104000163 |
News Archive
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of PRM-151 will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology, being held May 1-5, 2011 in Ft. Lauderdale, FL.
Silence Therapeutics plc announces the issuance of two new patents by the United States Patent and Trademark Office (USPTO) which are broadly directed to double-stranded short interfering RNA (siRNA) sequences against the validated cancer targets epidermal growth factor receptor related protein (EGFR-RP) and vascular endothelial growth factor receptor 1 (VEGFR1).
Using a robot to treat brain aneurysms is feasible and could allow for improved precision when placing stents, coils and other devices, according to late breaking science presented today at the American Stroke Association's International Stroke Conference 2020.
Researchers for the first time have developed a method to track through the human body the movement of polycyclic aromatic hydrocarbons, or PAHs, as extraordinarily tiny amounts of these potential carcinogens are biologically processed and eliminated.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sedrick A Salisbury, MD Po Box 1193, Corvallis, OR 97339-1193 Ph: () - | Dr Sedrick A Salisbury, MD 325 Park St, Lebanon, OR 97355-4229 Ph: (541) 451-7200 |
News Archive
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of PRM-151 will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology, being held May 1-5, 2011 in Ft. Lauderdale, FL.
Silence Therapeutics plc announces the issuance of two new patents by the United States Patent and Trademark Office (USPTO) which are broadly directed to double-stranded short interfering RNA (siRNA) sequences against the validated cancer targets epidermal growth factor receptor related protein (EGFR-RP) and vascular endothelial growth factor receptor 1 (VEGFR1).
Using a robot to treat brain aneurysms is feasible and could allow for improved precision when placing stents, coils and other devices, according to late breaking science presented today at the American Stroke Association's International Stroke Conference 2020.
Researchers for the first time have developed a method to track through the human body the movement of polycyclic aromatic hydrocarbons, or PAHs, as extraordinarily tiny amounts of these potential carcinogens are biologically processed and eliminated.
› Verified 4 days ago
Dr. Robert D. Wimmer, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 525 N Santiam Hwy, Lebanon, OR 97355 Phone: 541-451-6427 Fax: 541-451-7520 | |
Cody Talbot, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 Mullins Dr Ste C2, Lebanon, OR 97355 Phone: 541-451-6413 | |
Dr. Jourdan Leigh Hull, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 525 N Santiam Hwy, Lebanon, OR 97355 Phone: 541-451-6479 Fax: 541-451-7085 | |
Dr. Randy J. Mccoy, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 325 Park St, Lebanon, OR 97355 Phone: 541-451-7200 | |
Dr. Mark Thomas Day, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 525 N Santiam Hwy, Lebanon, OR 97355 Phone: 541-258-2101 | |
Dr. Dana L. Kosmala, D.O. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 675 N 5th St Ste 200, Lebanon, OR 97355 Phone: 541-451-6282 |